4166-53-4

Basic information

• Product Name: 3-METHYLGLUTARIC ANHYDRIDE
• Synonyms: 2H-Pyran-2,6(3H)-dione, dihydro-4-methyl-;BETA-METHYLGLUTARIC ANHYDRIDE;4-METHYLDIHYDRO-2H-PYRAN-2,6(3H)-DIONE;4-METHYL-DIHYDRO-PYRAN-2,6-DIONE;3-METHYLGLUTARIC ANHYDRIDE;3-Methylglutaricanhydride,98%;3,4-Dihydro-4β-methyl-2H-pyran-2,6(5H)-dione;3-Methylpentanedioic anhydride
• CAS NO: 4166-53-4
• Molecular Formula: C₆H₈O₃
• Molecular Weight: 128.13
• EINECS: 224-020-6
• Product Categories: Anhydride Monomers;Monomers;Polymer Science
• Mol File: 4166-53-4.mol
• Article Data: 15

Chemical Properties

• Melting Point: 42-46 °C(lit.)
• Boiling Point: 180-182 °C25 mm Hg(lit.)
• Flash Point: >230 °F
• Appearance: White/Crystalline Low Melting Solid
• Density: 1.2072 (rough estimate)
• Vapor Pressure: 0.00119mmHg at 25°C
• Refractive Index: 1.4585 (estimate)
• Storage Temp.: Inert atmosphere,Room Temperature
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• Sensitive: Moisture Sensitive
• Stability: Moisture Sensitive
• BRN: 114457
• CAS DataBase Reference: 3-METHYLGLUTARIC ANHYDRIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-METHYLGLUTARIC ANHYDRIDE(4166-53-4)
• EPA Substance Registry System: 3-METHYLGLUTARIC ANHYDRIDE(4166-53-4)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• F: 10-21
• Hazardous Substances Data: 4166-53-4(Hazardous Substances Data)

Usage

Description

3-METHYLGLUTARIC ANHYDRIDE is an organic compound that serves as a crucial reagent in the synthesis of various pharmaceutical compounds. It is characterized by its anhydride functional group and a methyl substituent on the glutaric acid backbone, which contributes to its unique chemical properties and reactivity.

Uses

Used in Pharmaceutical Industry:
3-METHYLGLUTARIC ANHYDRIDE is used as a key intermediate in the synthesis of oxoeicosanoid receptor antagonists. These antagonists play a significant role in modulating the stimulatory effects on cell types involved in mediating immunity-based inflammatory reactions. By targeting these receptors, 3-METHYLGLUTARIC ANHYDRIDE contributes to the development of therapeutic agents that can potentially treat a range of inflammatory and immune-related disorders.

InChI:InChI=1/C6H8O3/c1-4-2-5(7)9-6(8)3-4/h4H,2-3H2,1H3

Upstream product

• 6280-15-5 3-methylpentanedial 
• 626-51-7 3-methyl glutaric acid 
• 5832-70-2 diethyl 2-cyano-3-methylpentanedioate 
• 4161-07-3 3-Methyl-glutarsaeure-mono--ester 
• 141-82-2 malonic acid 
• 123-63-7 paracetaldehyde 
• 67-56-1 methanol 

Downstream Products

• 27151-65-1 3-methyl-1,5-pentanedioic acid monomethyl ester 
• 25883-04-9 3-(Acetyl-methyl-amino)-5-(4-carboxy-3-methyl-butyrylamino)-2,4,6-triiodo-benzoic acid 
• 4962-66-7 N-(3,4-Dimethoxyphenaethyl)-β-methylglutarsaeure monoamid) 
• 92864-22-7 5-(2,4-Dimethyl-phenyl)-3-methyl-5-oxo-pentanoic acid 
• 4457-71-0 3-methylpentane-1,5-diol 
• 71135-23-4 (R,S)-3-methyl-4-aminobutyric acid 
• 858795-25-2 3-methyl-glutaric acid bis-phenethylamide 
• 566151-57-3 1-(4-methoxybenzyl)-4-methylpiperidine-2,6-dione 
• 545376-21-4 (S)-1-(4-chlorophenoxy)-2-(4-methyl-2,6-piperidindion-1-yl)propane 
• 545376-19-0 (R)-1-(4-chlorophenoxy)-2-(4-methyl-2,6-piperidindion-1-yl)propane 
• 545376-25-8 (S)-1-(4-chlorophenoxy)-3-(4-methyl-2,6-piperidindion-1-yl)butane 
• 545376-23-6 (R)-1-(4-chlorophenoxy)-3-(4-methyl-2,6-piperidindion-1-yl)butane 
• 26643-18-5 1-benzyloxy-4-methyl-piperidine-2,6-dione 
• 63473-60-9 (R)-3-methylpentanedioic acid monomethyl ester 

Relevant articles and documents

Total Synthesis of Huperzine R

A total synthesis of huperzine R was accomplished. Intramolecular cycloaddition of a nitrile oxide and reductive cleavage of the resulting isoxazoline induced sequential cleavage of the C-C and C-O bonds to form the characteristic bicyclic lactam core with an enone moiety. Construction of the butenolide moiety from the enone afforded huperzine R.

LIPID PRODRUGS OF PREGNANE NEUROSTEROIDS AND USES THEREOF

The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.

LIPID PRODRUGS OF BTK INHIBITORS AND USES THEREOF

The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, and methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.